19 Sep 2007 03:00 AM
New Phase 3 Study In Treatment-Naive Adults With HIV Evaluates Efficacy And Safety Of Once-Daily PREZISTA(TM)/ritonavir Vs. KALETRA(R)
Results from a new ongoing,
randomized, controlled, open-label Phase 3 study showed that 84 percent of
treatment-naive HIV-1…
